NME2 expression is associated with a bad prognosis in lung cancer [159], HCC, BCa, colorectal carcinoma, neuroblastoma, prostate cancer, gastric cancer, and chronic myeloid leukemia [160] has been reported to inhibit cell migration and invasion. Here, NME2 is linked to prostate cancer.